Queensland biotechnology company Microbio expects clinical evaluation trials of its InfectID-BSI tests to be completed next month, prior to launching in the European market.

US based Landrich Group is managing the trials at four locations in the USA, South America, India and Australia, undertaking a performance evaluation of Microbio InfectID assays.

Read more in the media release: 220412_Independent assessment of Microbio’s BSI test expected to be completed in May

Contact us

Complete this form to request more information on purchasing InfectID, including the COVID-19 Replicating assay, new product developments, or other enquiries.
  • This field is for validation purposes and should be left unchanged.